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Targeted-pig trial on safety and 
immunogenicity of serum-derived 
extracellular vesicles enriched 
fractions obtained from Porcine 
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infections
Sergio Montaner-Tarbes  1,2, Elena Novell3, Vicens Tarancón3, Francesc E. Borrás1,4, 
Maria Montoya1, Lorenzo Fraile1,2 & Hernando A. del Portillo  1,4,5,6
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the 
most important swine diseases with a significant economic burden worldwide. Unfortunately, available 
vaccines are partially effective highlighting the need of novel approaches. Previously, antigenic viral 
proteins were described in serum-derived extracellular vesicles (EVs) from pigs previously infected with 
PRRSV. Here, a targeted-pig trial was designed to determine the safety and immunogenicity of such 
extracellular vesicles enriched fractions. Our results showed that immunizations with EV-enriched 
fractions from convalescence animals in combination with montanide is safe and free of virus as 
immunizations with up-to two milligrams of EV-enriched fractions did not induce clinical symptoms, 
adverse effects and detectable viral replication. In addition, this vaccine formulation was able to elicit 
specific humoral IgG immune response in vaccinated animals, albeit variably. Noticeably, sera from 
vaccinated animals was diagnosed negative when tested for PRRSV using a commercial ELISA test; 
thus, indicating that this new approach differentiates vaccinated from infected animals. Lastly, after 
priming animals with EV-enriched fractions from sera of convalescence animals and boosting them with 
synthetic viral peptides identified by mass spectrometry, a distinctive high and specific IFN-γ response 
was elicited. Altogether, our data strongly suggest the use of serum EV-enriched fractions as a novel 
vaccine strategy against PRRSV.
Recent estimates calculate that the world human population will reach near 9,6 billion people by 2050 and the 
United Nations Food and Agriculture Organization (FAO) estimates that in order to feed this population the 
overall food production will need to increase by 70%1. Undoubtedly, veterinary vaccines that preserve animal 
health and improve production will play an essential role in reaching this goal. Moreover, they will reduce the use 
of antibiotics as they are escalating into a global health crisis. To reach this goal, novel vaccination approaches 
are desperately required as classical and live-attenuated vaccines are far from being totally safe and efficacious in 
animal diseases2.
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) causes one of the most important dis-
eases of veterinary medicine3. Recent economical estimates in the United States, where the disease is highly prev-
alent, indicate more than 600 million $ loses each year4. Current vaccines against PRRSV use modified live or 
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attenuated virus, small peptides, vectored vaccines, inactivated virus and subunit vaccines5. Nevertheless, avail-
able vaccines have serious limitations such as little protective immunity, possible reversion to virulence, inability 
to induce long lasting and heterologous protection among European and American genotypes, and high antigenic 
and genetic differences of strains. All together, these limitations indicate that new alternatives to conventional 
vaccines are needed trying to control and eventually eradicating PRRSV.
Extracellular vesicles (EVs) are gaining increase scientific attention as novel vaccines against infectious dis-
eases, including animal diseases of veterinary importance6–9. Our group previously determined that EVs obtained 
from serum of animals that had overcome a PRRSV infection were free of virus as detected by a commercial and 
sensitive qRT-PCR test and contained antigenic viral-specific cargo7. Here, we report a targeted-pig safety and 
immunogenicity trial by immunizing pigs with serum-derived EV-enriched fractions from convalescence ani-
mals. Our results revealed that these EV-enriched fractions are safe, free of virus and contained immunogenic 
viral peptides capable of eliciting specific humoral and cellular immune responses. Moreover, this approach seems 
capable of differentiating vaccinated from infected animals (DIVA).
Material and Methods
Ethical statement for experimental procedures. All studies were approved by the ethical committee 
of Universitat de Lleida and the Departament d’Agricultura, Ramaderia, Pesca, Alimentació I Medi rural (Section 
of Biodiversity and hunting) under licence DAAM 7700. All procedures and experiments in this research were 
performed in accordance with guidelines and regulations of University of Lleida and the Department of Animal 
Sciences of this University under the supervision of a veterinary.
Serum samples. Serum was obtained from five individual large white-Landrace pigs of 80–100 kg of body 
weight that had suffered a PRRSV natural infection. Animals were anesthetized and approximately 1 L of periph-
eral blood from each animal was collected by venous puncture. Afterwards, animals were humanely euthanized 
according to procedures approved by the University of Lleida. Blood was collected into 50 mL Falcon tubes 
to facilitate separation of sera and minimize haemolysis. Viral as well as serological status of animals against 
PRRSV antigens were analysed, by an independent laboratory specialized in diagnosis of porcine diseases (Grup 
de Sanejament Porci (http://www.gsplleida.net/cat) using RT-PCR TaqMan® NA/EU PRRSV Reagents (Applied 
Biosystems) and IDEXX PRRS X3 Antibody Test (IDEXX) following their own standard operational procedures. 
All those animals were negative by PCR and positive for antibodies against PRRSV in serum.
EVs enrichment and isolation. Enrichment of serum-derived EVs was obtained through ultracentrifu-
gation10 followed by Size Exclusion Chromatography (SEC) using our own standard methodologies11. Sera sam-
ples were centrifuged for 2 hours at 100.000 × g at 4 °C and resuspended in ten mL of PBS (final volume) before 
loading into PuriFlash Dry Load Columns 80 G (Interchim) filled with 100 mL of sepharose CL-2B (separation 
matrix) and five mL fractions collected for further analysis. Nanoparticle tracking analysis (NTA), flow cytometry 
(FACS/culture supernatant monoclonal antibodies against EVs tetraspanins CD9, CD63, CD81 and CD5L from 
Abcam ab45408) and proteomic analyses (liquid chromatography/mass spectrometry: LC-MS/MS) were carried 
out as previously described7. Protein concentration was determined by bicinchoninic acid assay protein assay 
(BCA Pierce protein quantification assay – Thermo Scientific)12 and used as vaccine dose unit. All those tests are 
recommended as standard proxy for characterization of extracellular vesicles and exosomes13.
Mass spectrometry. Liquid chromatography (nanoLCULTRA-EKSIGENT) followed by mass spectrometry 
(LTQ Orbitrap Velos - Thermo Fisher) was used to identify viral proteins associated to EVs enriched fractions as 
previously described7. Briefly, protein identification was done using RAW data from five different animals from 
which EVs enriched fractions were analysed by LC-MS/MS and Maxquant software v1.5 excluding those hits 
identified by reverse database, marked as contaminant and identified by modifications. Only those proteins with 
2 or more unique peptides and 1% FDR were used for further analyses.
Synthetic peptides. After LC-MS/MS identification of PRRSV proteins associated with serum-derived EVs 
enriched fractions (Supplementary Table T1), two different algorithms were used to examine matching regions 
between our identified peptides (LC-MS/MS) and possible B-cell epitopes or antigenic regions within the protein14,15. 
Peptides corresponded to the Envelope glycoprotein (ENV), Nucleocapsid (N) and polyprotein 1a (pp1a) viral proteins. 
Matching regions were detected and then evaluated for suitable Swine leukocyte antigen binding (SLA) by NetMHCpan 
4.016,17. Those with higher score were used to synthetized 35aa peptides (Department of Experimental and Health 
Sciences – Peptide Synthesis Facility of Universitat Pompeu Fabra at Centre for Genomic Regulation (Barcelona – 
Spain) according to their own standard operation procedures. Characterization of each synthetic peptide was carried 
out using an A-HPLC with a Column Luna C18 (4.6 × 50 mm, 3 um; Phenomenex), a Gradient: Linear B (0.036% TFA 
in MeCN) into A (0.045% TFA in H2O) over 15 minutes with a flow rate of 1 mL/min and detection at 220 nm. All pep-
tides were 90% pure and were resuspended in ultrapure H2O (MiliQ water), aliquoted and stored in −20 °C until use.
Safety pig targeted trial. Fifteen PRRSV negative pigs were divided into groups with food and water ad 
libitum in an experimental farm (Centre d’Estudis Porcins, Torrelameu, Spain) under veterinarian supervision. 
EV-enriched fractions from animals that had overcome the disease were combined with Montanide ISA 206 VG 
(SAFIC-ALCAN, batch. T83571 - gently provided by SEPPIC) in a 1:1 ratio using three different EV-enriched frac-
tion protein concentrations (0.3, 0.5 and 1 mg) and injected intra-muscularly (IM) in one side of the neck (Table 1). 
Each animal received 2 mL of the formulation in two different time points. Serum samples were drawn at 0, 21 and 
51 days post initial vaccination (dpv). Collection of samples, maintenance and culling of pigs were performed as 
approved by the animal use and care committee protocol of the Universitat de Lleida and the Departament d’Agricul-
tura, Ramaderia, Pesca, Alimentació I Medi rural (Section of Biodiversity and hunting) under licence DAAM 7700.
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Immunogenicity pig-targeted trial and challenge. A heterologous prime-boost vaccination 
approach18 was performed using serum derived EV-enriched fractions as a prime antigen (2 doses) and a boost 
with the viral synthetic peptides identified by LC-MS/MS. First, thirty-three PRRSV negative pigs were divided 
into groups with food and water ad libitum in an experimental farm (Centre d’Estudis Porcins, Torrelameu, 
Spain) under veterinarian supervision. To test immunogenicity, 14 animals received one immunization and a 
boost containing 2 mL with 1 mg of EV-enriched fractions in different timepoints (Group A: completely naïve 
animals/Group B: previously received vaccines against circovirus and porcine ileitis). The second boost given to 
all animals consisted of a 900 ug peptide mix corresponding to 300 ug of each viral peptide. As a control of a clas-
sical vaccination approach, two groups (7 pigs each) were vaccinated only with synthetic peptides (0.5 mg of each 
peptide) in combination with two different adjuvants (Group C: Montanide ISA201 and Group D: Montanide 
ISA206) in two different time-point doses and a boost with 300ug of the same peptide mix with the respective 
adjuvant and as a negative control, only PBS was injected to 5 animals (Fig. 1; Table 2).
Serum samples were taken at 0, 21, 42 and 63 days post initial vaccination (dpv). Whole blood in EDTA tubes 
was collected at days 0 and 63. Collection of samples, maintenance and euthanasia of pigs were performed as 
approved by the animal use and care committee protocol of Universitat de Lleida and the Departament d’Agricul-
tura, Ramaderia, Pesca, Alimentació I Medi rural (Section of Biodiversity and hunting) under licence DAAM 7700.
ELISA tests. All sera samples were also blindly evaluated by a commercial ELISA (IDEXX PRRS X3 
Antibody Test, IDEXX) to detect PRRSV antibodies following their own standard operation procedures (Grup de 
Sanejament Porcí – Lleida, Spain. http://www.gsplleida.net/cat).
Circulating IgG antibodies from vaccinated pigs in the immunogenicity trial were also evaluated by an indi-
rect ELISA test against the synthetic peptides (ENV, N and pp1a). Plates were coated overnight at 4 °C with 
each peptide (5 ug/mL diluted in 50 mM Carbonate-Bicarbonate buffer, pH 9.6). Sera samples (1/100) were incu-
bated for 1 h at room temperature, washed and incubated with secondary antibody Goat anti-Pig IgG (Fc): HRP 
(AbSerotec AAI41P) at 1/10000 dilution. Optical density was measured at 450 nm using Varioskan equipment 
(Thermo Scientific).
Antibodies were also examined using attenuated virus as coating antigen. Briefly, viral particles were diluted to 
reach 104 particles per 50 uL with Carbonate bicarbonate buffer (pH 9.6). Plates were incubated overnight at 4 °C 
to ensure particle viral attachment to the plates. Plates were washed and then blocked with PBS 1×/5% non-fat 
dry milk. After 3 washes, 1/100 dilution of all sera were incubated at room temperature for 1 h, then washed 3X 
and incubated with secondary antibody Goat anti-Pig IgG (Fc): HRP (AbSerotec AAI41P) at 1/10000 dilution. 
Optical density was measured at 450 nm using Varioskan equipment (Thermo Scientific).
Figure 1. Scheme of safety and immunogenicity targeted-pig trial. Timeline of immunizations was the same 
for both strategies. (a) For safety trial, animals receive two doses of EVs injected intramuscularly (Day 0 and 
21) and euthanised at day 51. (b) For immunogenicity trial, animals received either two doses of EV-enriched 
fractions or synthetic viral peptides (day 0 and 21) and all then boosted with synthetic viral peptides (day 42). 
All animals were euthanised at day 63. Serum samples were collected in all timepoints.
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IFN-γ ELISPOT. For evaluation of IFN-γ production, ten mL aliquots of whole blood in EDTA tubes 
were collected. Peripheral mononuclear cells (PBMCs) were isolated by gradient centrifugation using Ficoll 
Hystopaque 1077 (Sigma-Aldrich) and washed twice with PBS 1×/2% FBS after which cell density and viability 
were measured by trypan blue staining. Cells were resuspended in complete media “CM” (RPMI 1640, 10% FBS, 
1% penicillin/Streptomycin) to have a final concentration of approximately 5 × 106 cells/mL.
For ELISPOT, plates (Millipore, Cat n° MAHAS4510) were coated with 1/100 dilution of capture antibody in 
50 mM carbonate/bicarbonate coating buffer pH 9.6 (Anti pig IFN-γ antibody clone P2G10 – BD Biosciences, cat 
n° BD-559961) and incubated overnight at 4 °C. Plates were washed twice with CM and blocked with 200uL of 
CM as blocking buffer for 2 hours at room temperature. Blocking buffer was discarded and all stimuli (synthetic 
viral peptides) were diluted in CM and added to the plate including a positive control (Lectin from Phaseolus 
vulgaris – Sigma Aldrich) and a negative control (CM alone). 100 uL of cell suspension was loaded to the plate 
and incubated for 48 hours at 37 °C and 5% CO2. Later, cells were washed out with 200uL MilliQ water and plates 
washed 3 times with 1X PBS/0.05% Tween 20. One hundred uL of 1/250 dilution of a biotinylated Mouse anti-pig 
IFN-γ clone P2C11 was loaded in the plate (BD Biosciences, Cat. n° BD-559958) and incubated 2 hours at room 
temperature. Detection was carried out using a 1/100 dilution of Streptavidin-HRP conjugate (BD Biosciences 
cat n° BD-557630) after which plates were washed four times with1X PBS/0.05% Tween 20 and incubated for 
20 min with 100 uL of non-soluble substrate AEC reagent (BD Biosciences cat n° BD-551951) to reveal spots. 
Developing of spots was stopped by washing plates with distilled water 3 times and IFN-γ spots were counted in 
an AID ELISPOT Reader. Production of IFN-γ was expressed as spot forming colonies per million of PBMCs in 
each well.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 7. The significance level 
(α) was set at p < 0.05. In the ELISPOT, significant differences between groups were determined using two-way 
analysis of variance followed by Sidak’s multiple-comparison test. For the ELISA results, Kruskal-Wallis test for 
non-paired data was applied, comparing the ranks of each group in a particular timepoint and statistically signif-
icant differences were expressed as p < 0.05 (*) and p < 0.01 (**).
Results
Characterization of serum-derived EV-enriched fractions from non-viremic animals. Size-
exclusion chromatography of EV-enriched fractions eluted in fractions 7–10, were analysed by bead-based 
flow-cytometry to determine the presence of CD63 and CD81, two tetraspanins widely used as exosomal mark-
ers. As shown in Fig. 2a, high MFI values confirmed their presence associated with EV-enriched fractions. To 
further validate these results, two other tetraspanins, CD9 and CD5L, were evaluated showing similar results 
(Supplementary Fig. 2). Of interest, CD5L gave the highest MFI of all tetraspanins tested. As previously reported7, 
NTA analysis revealed a mean size EVs distribution of 100–200 nm (Fig. 2b) and cryo-TEM confirmed this size 
distribution (Fig. 2c). These data thus indicate the large heterogeneity of plasma-derived EVs. Scaled-up produc-
tion of serum derived EV-enriched fractions, allowed to accurately and precisely determine protein concentration 
from individual SEC fractions by BCA. We calculated circa 3 mg of protein associated to EVs enriched fractions 
for every 180 mL of serum.
Proteomic analysis. Individual proteomic analysis of serum-derived EVs enriched fractions from five ani-
mals used in these vaccination trials revealed peptides corresponding to viral proteins, pp1a, Envelope glycopro-
tein and Nucleocapsid proteins (Fig. 3 and Supplementary Table T1). Of note, other viral proteins were detected 
in the preparations but were discarded due to our filtering criteria (FDR < 1% and at least two peptides from 
individual proteins).
Group Pigs Priming antigen Boost antigen Adjuvant Route
PBS 5 PBS PBS N/A IM
Group A 7 Exosomes (1 mg)/two doses Viral peptides (300 ug each)/one dose Montanide ISA 206vg IM
Group B 7 Exosomes (1 mg)/two doses Viral peptides (300 ug each)/one dose Montanide ISA 206vg IM
Group C 7 Viral peptides (500 ug each/two doses) Viral peptides (300 ug each)/one dose Montanide ISA 201 vg IM
Group D 7 Viral peptides (500 ug each/two doses) Viral peptides (300 ug each)/one dose Montanide ISA 206 vg IM
Table 2. Experimental groups for immunogenicity trial.
Group Pigs Antigen Total ug (1 mL) Adjuvant (1 mL) Route
Exosomes 1 mg + M 3 Exosomes 1000 Montanide IM
Exosomes 1 mg 3 Exosomes 1000 N/A IM
Exosomes 0.5 mg + M 3 Exosomes 500 Montanide IM
Exosomes 0.5 mg 3 Exosomes 500 N/A IM
Exosomes 0.3 mg + M 3 Exosomes 300 Montanide IM
Table 1. Experimental groups for exosome vaccination safety trial.
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After viral peptide identification, we used two different algorithms to predict their immunogenicity14–16,19. 
Interestingly, we found immunogenic regions, possible B-cell epitopes and decamers that fit as strong binders in 
several SLA pockets for those proteins matching with peptides detected in EVs enriched fractions. Figure 3 shows 
a schematic representation of the identification pipeline.
Safety. Three different doses of EV-enriched fractions derived from PRRSV convalescent swine sera were 
formulated in montanide and tested in nine animals and two different doses without adjuvant were injected in 
six animals to assess the risk of viral presence and adverse effects of these preparations (Table 1). As a first safety 
control, batches were tested prior to vaccinations by a sensitive RT-PCR. None of the batches obtained individ-
ually from 180 mL of sera revealed the presence of viral particles. Moreover, none of the animals showed clinical 
signs associated to PRRSV, nor secondary effects due to vaccine/adjuvant preparation even after two doses of 1 mg 
of EV-enriched fractions. Importantly, EV-enriched fractions containing viral proteins did not induce a positive 
result to the gold standard ELISA test (IDEXX X3 PRRSV) suggesting that this vaccination approach could allow 
to differentiate vaccinated from infected animals (DIVA).
Immunogenicity. To test the immunogenicity of serum derived EV-enriched fractions, fourteen animals 
were immunized twice with 1 mg of EV-enriched fractions formulated in montanide and boosted a third time 
with viral peptides (identified by LC-MS/MS). To compare the immunological response, two groups using a 
classical vaccination approach with peptides and adjuvants were used (Fig. 1). As expected from the safety data, 
neither clinical signs related to PRRSV infections, nor secondary effects were observed in any of these fourteen 
animals. Moreover, similar to the safety trial, all animals remained negative for the gold standard ELISA test for 
PRRSV virus, indicating that epitopes present in EVs enriched fractions and in our in vitro synthetic viral pep-
tides are capable of differentiating animals infected with the virus (positive results in the ELISA test) and those 
vaccinated with our novel strategy.
To assess humoral immune response, blood was taken from all animals at days 0, 21, 42 and 63 
post-vaccination. IgG levels against the different synthetic peptides used in our immunisation approach were 
determined by ELISA. As expected, all animals were negative for antibodies against these viral peptides at 
day 0 (Fig. 4). At 21dpv, only groups C and D showed a response to the ENV peptide. At day 63dpv, higher 
antibody immune responses were detected in animals vaccinated and boosted with peptides as opposed to 
Figure 2. Characterisation of serum-derived enriched EV-fractions from scale-up process. (a) Flow 
cytometry analysis of CD63 and CD81. MFI, Median Fluorescence Intensity. Protein concentration by the 
Pierce bicinchoninic acid assay (BCA assay) is shown mg/mL. (b) NTA profiles of EV-enriched fractions from 
size exclusion chromatography (SEC). Concentration is shown in particle/ mL. (c) Electron microscopy. (c) 
Representative TEM images. Scales in nanometers (nm).
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EVs-EVs-peptide ones (heterologous prime-boost) even though Groups A and B started to show a response 
against ENV and N but lower than Groups C and D. Moreover, based on these results, the ENV peptide seemed 
the most immunogenic from the ones tested, followed by the N peptide of peptide and the pp1a peptide (Fig. 4). 
We took advantage of the immune sera from animals that had seroconverted against the ENV and Nucleocapsid 
proteins to demonstrate their association with EVs used in these trials. Thus, western blot analysis of EVs used 
in vaccinations were performed using pre-immune and immune sera from two animals primed with EVs and 
boosted with peptides. These animals seroconverted after the last boost to the nucleocapsid and ENV proteins, 
albeit variably. Noticeably, only immune sera specifically recognized these proteins (Supplementary Fig. S3). 
These results thus demonstrate that viral sequences from these peptides were associated with EVs used in vacci-
nations. Experiments to identify residues within the 35 aa synthetic peptides representing these proteins in the 
context of SLA can be considered as part of a next series of targeted-pig trials including challenge.
To assess cellular immunity, numbers of cells producing IFN-γ were measured by ELISPOT. Excepting for one 
animal in group D, remaining animals in groups C and D did not produce IFN-γ. Noticeably, there was a signif-
icant increase in number of IFN-γ producing cells with values from 60 to 350 SFCx106 PBMCS on groups A and 
B vaccinated with EV-enriched fractions obtained from convalescence animals (Fig. 5).
Discussion
Here, immunization of pigs with up-to two milligrams of EV-enriched fractions from sera of PRRSV convales-
cence animals demonstrated that they were free of virus and did not cause adverse effects. In addition, immu-
nization of pigs with EV-enriched fractions followed by boosts with predicted immunogenic synthetic peptides 
from the ENV, N and pp1a proteins elicited specific humoral IgG immune responses not detected by a widely 
used PRRSV-diagnostics commercial test; thus, suggesting that this vaccination approach is able of differentiating 
infected from vaccinated animals. Lastly, such prime-boost approach elicited high and specific IFN-γ responses 
in comparison with immunizations using peptides alone.
Previous studies identified viral peptides corresponding to the Nucleocapsid, and pp1a proteins in 
serum-derived EV-enriched fractions from pigs that had overcome PRRSV infections7. Here, we confirm such 
results as we identified viral peptides from these same two proteins, in addition to peptides from envelope GP5 
protein, in individual mass spectrometry studies of five different convalescence animals. Our data strongly indi-
cate that there is selective viral antigen-cargo associated with EV-enriched fractions from convalescence animals. 
The Nucleocapsid protein is an important structural protein which after cytoplasmic synthesis migrates to the 
nucleus suppressing expression of type I interferons20,21. Moreover, interactions between this structural protein 
and antigen presenting cells in the presence of viral induced IL-10 can lead to and alteration of APC functions21. 
pp1a encodes 10 non-structural proteins, NSPs, and expression of PRRSV nsp1α/β and nsp2 were found to exert 
strong inhibitory effects on IFN-β promoter activation22. In addition, it has been recently discovered that the 
pp1a region of highly pathogenic PRRSV strains plays an important role in inducing neutralizing antibodies in 
piglets23. The GP5 protein contains epitopes involved in antibody dependent virus neutralization, protection, 
cell recognition and binding24. However, it remains to be studied which EV component(s) are responsible for 
Figure 3. Protein identification pipeline from PRRSV convalescent sera EV-enriched fractions. Liquid 
chromatography (nanoLCULTRA-EKSIGENT) followed by mass spectrometry (LC-MS/MS) of EV-enriched 
fractions identified viral peptides with a FDR < 1% and at least two peptides from the same protein. Two 
different algorithms were used to examine matching regions between our identified peptides (LC-MS/MS) and 
possible B-cell epitopes or antigenic regions within the protein14,15.
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the immunogenicity presented in this work. EVs include sets of immune related proteins such as MHC that 
could contribute to elicit a better immune response25. Recently, we have analyzed the peptides present in EV by 
NetMHCSpan and our preliminary results identified peptide sequences with the theoretical ability to bind to 
certain MHC (SLA in the case of swine). Moreover, these peptides were predicted as strong binders for different 
SLA alleles (data not shown). If these predictions are confirmed, such antigenic peptides in the EV cargo could 
participate in developing specific immune responses.
Our data thus strongly suggest that novel viral antigenic peptides can be discovered in serum EV-enriched 
fractions from animals that were free of virus in peripheral circulation. As it is known that PRRSV infection can 
last for months in internal tissues3,26,27, it is tempting to speculate that such cryptic infections in lymphoid tissues 
might release into circulation EV-enriched fractions with selected cargo eliciting immune responses capable of 
maintaining animals with undetected viremias in peripheral circulation and with no clinical symptoms.
Figure 4. Evaluation of antibody immune response against peptides from D0 to D63 in swine sera. PRRS viral 
peptides were used in ELISA tests. Graphs refer to immune recognition of viral peptides after vaccination at 
different immunization days post vaccination. (a) Day cero (b) Day 21 (c) Day 42 (d) Day 63. Vaccination with 
PBS was used as a control during whole experiment. *p < 0.05, **p < 0.01. OD, optical density.
Figure 5. IFN-γ production after stimulation of swine PBMCs with viral peptides (mix) at days 0 and 63 post 
vaccination. IFN- γ producing cells were measured by ELISPOT at day cero and 63DPV. Results were compared 
(0dpv vs 63dpv response) using two-way ANOVA multiple comparison test. Statistically significant differences 
were observed only in exosome vaccinated groups between pre-vaccinated sera and 63dpv sera. *p < 0.05, 
**p < 0.01.
www.nature.com/scientificreports/
8SCIEnTIFIC RePoRTS |         (2018) 8:17487  | DOI:10.1038/s41598-018-36141-5
To scale-up the production of EV-enriched fractions for the safety and immunogenicity trials, serum samples were 
concentrated 100-times through ultracentrifugation and size exclusion chromatography (see Methods). To demon-
strate that these preparations were free of virus, a sensitive qRT-PCR capable of detecting 100 particles/mL (Applied 
Biosystems) was firstly performed showing that they did not contain viral RNA. Next, we injected increasing doses 
of EV-enriched fractions into nine different animals in safety trial and fourteen animals in the immunogenicity trial 
(Fig. 1). Results demonstrated that injections of up to two milligrams of serum-derived EV-enriched fractions from 
these animals did not cause any clinical symptoms and were free of virus (Tables 1 and 2). Of interest, a recent publica-
tion suggested that exosomes from PRRSV-infected cells and free of virus act as vehicles for intercellular transmission28. 
Whether these seemingly discrepant results are due to in vitro vs in vivo studies, remains to be determined.
Current vaccine approaches against PRRSV have met little success in developing broad neutralizing antibodies 
and no correlate of protection is presently available with antibody levels29. Moreover, available tests for measur-
ing neutralizing antibodies are difficult to interpret as the PRRSV isolate used for testing are not field strains but 
cell-cultured adapted30. Our data demonstrated that our prime-boost approach elicited specific IgG antibodies. 
However, even though all animals seroconverted at the end of the study, titers and recognition against individual 
peptides varied significantly among groups (Fig. 3). Whether these antibodies contain high quality neutralizing 
antibodies remains to be determined. Serum-derived EV-enriched fractions represent a complex mixture of vesi-
cles release from widely different type of cells31. Therefore, it is reasonable to speculate that serum EVs containing 
viral peptides represent a very small percentage of circulating EVs, partly explaining the low seroconvertion rate in 
EV-vaccinated groups when compared with peptide vaccination added to individual variability observed in this trial.
Highly pathogenic PRRSV strains are emerging all over the world with cases mainly in Asia, America and 
some in Europe through recombination of wild type viruses with vaccine strains30,31 making a top priority to find 
a test that allow identification of vaccinated animals from those that overcome the disease (DIVA). As several 
current vaccination approaches are using modified live viruses, deletion mutants and chimeric viruses are being 
tested with the idea of solving the above mentioned problem32. Noticeably, based on a gold standard commercial 
method (IDEXX PRRSV x3 Ab test), sera from all animals that seroconverted were diagnosed free of virus sug-
gesting that this vaccination approach can differentiate infected from vaccinated animals.
Priming with EV-enriched fractions and boosting with viral peptides induced a high and specific cellular 
IFN-γ immune response above 300 SFCx106 PBMCs in EVs vaccinated groups, that was not present in the 
peptide-vaccinated group. The fact that viral peptides alone were not able to stimulate immune cells in vivo and 
EV-peptide vaccination approach could, made this a new and exciting opportunity to evaluate the role of EV 
during and post natural infection, as well as their role in viral clearance and immunity. Our result was remarkable 
when considering that in natural PRRSV infections, T cell immune responses are usually weak and delayed33, 
as well as variable appearing 4–6 weeks after infection34. Moreover, infected pigs show an important decrease in 
CD8+ T-cells and IFN-γ production and a reduction of 50 to 80% of NK cell cytotoxicity from day 7 to 24 post 
infection maybe due to increased IL-4 levels35.
Interestingly, exosomes are vehicles of proteins and nucleic acids acting in intercellular communication and 
antigen presentation36–39. Thus, serum-derived EVs from convalescence sera, bearing viral proteins and other 
immune-related proteins could be delivered to sites where memory cells are present in higher frequencies and 
activate effector memory T cells. In the absence of supporting data, this hypothesis remains to be proved. Such 
mechanism, however, has been recently shown to be elicited by reticulocyte-derived exosomes from infections in 
an experimental rodent malaria model40.
Because of their ability to modulate the immune response, exosomes are presently being explored as novel 
therapeutic agents against infectious diseases. Pioneering studies demonstrated that macrophages infected with 
Mycobacterium bovis secreted exosomes inducing bacterial-specific pro-inflammatory activity41. Similar results 
were obtained with exosomes from macrophages infected with Mycobacteium tuberculosis and this response was 
also evident in other infectious diseases caused by intracellular pathogens, Salmonella typhimurium, Toxoplasma 
gondii, Plasmodium yoelii as well as in other parasitic diseases from worms and protozoa41,42. Remarkably, using 
serum-derived CD80+ and CD80- enriched exosomes from Eimeria infected chicken induced increased num-
bers of intestinal and spleen cells secreting Th1 (IL-2, IL-6, IFN-γ) and Th2 (IL-4) cytokines, compared with 
unimmunized controls. In addition, in the case of Eimeria, CD80+ EVs induced a stronger immune response 
with increased numbers of IFN-γ and IL-2 producing cells (in gut and spleen as well) and greater protective 
immunity following E. tenella challenge, as measured by weight gain, feed efficiency, parasite shedding, and intes-
tinal lesions9. Altogether, the data from several studies strongly support the use of EVs and exosomes as a novel 
vaccine approach against veterinary diseases of economic importance.
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